Effects of Ramipril and Telmisartan on Plasma Concentrations of Low Molecular Weight and Protein Thiols and Carotid Intima Media Thickness in Patients with Chronic Kidney Disease

Table 1

Demographic and clinical characteristics of CKD randomized groups.

	CKD ()	Group 1 (); Telmisartan/ramipril; 40/5 mg/day	Group 2 (); Telmisartan; 80 mg/day
	Mean ± SD; or median (IQR)	Mean ± SD; or median (IQR)	Mean ± SD; or median (IQR)
Sex, F/M (% F)	8/16 (33%)	4/8 (33%)	4/8 (33%)
Age, years	60 ± 12	62 ± 12	58 ± 13
Systolic BP, mmHg	133 ± 13	132 ± 13	133 ± 14
Diastolic BP, mmHg	80 ± 9	82 ± 8	77 ± 9
Creatinine, mg/dL	1.6 (1.1–2.1)	1.6 (1.0–2.3)	1.7 (1.3–2.0)
GFR, mL/min per 1.73 m^2	48 (32–66)	48 (22–71)	48 (34–66)
Proteinuria, g/24 h	0.95 (0.30–2.35)	0.52 (0.28–2.49)	1.28 (0.36–2.35)
IMT, mm	0.90 (0.73–1.00)	0.95 (0.72–1.05)	0.88 (0.73–1.00)
Total LMW thiols
t-CysGly, µmol/L	30.2 ± 8.6	31.6 ± 8.8	28.8 ± 8.4
t-Hcy, µmol/L	17.0 (12.1–24.4)	16.3 (12.1–26.3)	19.2 (11.8–23.7)
t-Cys, µmol/L	381 ± 98	391 ± 89	370 ± 109
t-GSH, µmol/L	7.5 ± 2.6	7.4 ± 2.1	7.6 ± 3.2
t-GluCys, µmol/L	5.8 (3.9–6.5)	5.7 (4.5–6.0)	5.4 (3.5–7.6)
Sum of total LMW thiols, µmol/L	444 ± 112	458 ± 106	432 ± 122
Reduced LMW thiols
r-Cys-Gly, µmol/L	6.2 ± 2.2	5.8 ± 1.6	6.6 ± 2.6
r-Hcy, µmol/L	0.24 (0.15–0.37)	0.20 (0.13–0.37)	0.29 (0.18–0.37)
r-Cys, µmol/L	21.6 ± 4.1	20.9 ± 4.7	21.9 ± 3.5
r-GSH, µmol/L	1.09 (0.78–1.46)	1.01 (0.74–1.31)	1.11 (0.85–1.67)
r-Glu-Cys, µmol/L	0.36 (0.26–0.46)	0.35 (0.22–0.58)	0.37 (0.27–0.44)
Sum of reduced LMW thiols, µmol/L	29.4 ± 5.9	28.4 ± 5.9	30.5 ± 6.0
Thiols redox status
LMW redox, %	0.072 ± 0.027	0.066 ± 0.023	0.078 ± 0.030
PSH, µmol/g prot	3.95 (3.31–4.80)	3.59 (3.23–4.15)	4.61 (3.39–5.80)